"The US Food and Drug Administration (FDA) has approved the tumor necrosis factor inhibitor adalimumab (Humira, AbbVie) for the treatment of moderate to severe hidradenitis suppurativa (HS), making it the first and only FDA-approved therapy"...
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of DALVANCE cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.
Adverse Reactions In Clinical Trials
Adverse reactions were evaluated for 1778 patients treated with DALVANCE and 1224 patients treated with comparator antibacterial drugs in seven Phase 2 and Phase 3 clinical trials. A causal relationship between study drug and adverse reactions was not always established. The median age of patients treated with DALVANCE was 47 years, ranging between 16 and 93 years old. Patients treated with DALVANCE were predominantly male (60%) and Caucasian (78%).
Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation
Serious adverse reactions occurred in 109/1778 (6.1%) of patients treated with DALVANCE and in 80/1224 (6.5%) of patients treated with comparator. DALVANCE was discontinued due to an adverse reaction in 53/1778 (3%) patients and the comparator was discontinued due to an adverse reaction in 35/1224 (2.8%) patients.
Most Common Adverse Reactions
The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%). The median duration of adverse reactions was 4.0 days in both treatment groups.
Table 1 lists selected adverse reactions occurring in more than 2% of patients treated with DALVANCE in clinical trials.
Table 1: Selected Adverse Reactions in Phase 2/3
Trials (Number (%) of Patients)
(N = 1778)
(N = 1224)
|Nausea||98 (5.5)||78 (6.4)|
|Vomiting||50 (2.8)||37 (3)|
|Diarrhea||79 (4.4)||72 (5.9)|
|Headache||83 (4.7)||59 (4.8)|
|Rash||48 (2.7)||30 (2.4)|
|Pruritus||38 (2.1)||41 (3.3)|
|* Comparators included linezolid, cefazolin, cephalexin, and vancomycin.|
The following selected adverse reactions were reported in DALVANCE treated patients at a rate of less than 2% in these clinical trials:
Hepatobiliary disorders: hepatotoxicity
Immune system disorders: anaphylactoid reaction
Investigations: hepatic transaminases increased, blood alkaline phosphatase increased, international normalized ratio increased.
Metabolism and nutrition disorders: hypoglycemia
Nervous System disorders: dizziness
Respiratory, thoracic and mediastinal disorders: bronchospasm
Skin and Subcutaneous Tissue Disorders: urticaria
Alanine Aminotransferase (ALT) Elevations
Among patients with normal baseline ALT levels, more DALVANCE than comparator treated patients had post-baseline ALT elevations greater than 3 times the upper limit of normal (ULN), 12 (0.8%) vs. 2 (0.2%), respectively including three subjects with post-baseline ALT values greater than 10 times ULN. Eight of 12 patients treated with DALVANCE and one comparator patient had underlying conditions which could affect liver enzymes, including chronic viral hepatitis and a history of alcohol abuse. In addition, one DALVANCE-treated subject in a Phase 1 trial had post-baseline ALT elevations greater than 20 times ULN. ALT elevations were reversible in all subjects. No comparator-treated subject with normal baseline transaminases had post-baseline ALT elevation greater than 10 times ULN.
Read the Dalvance (dalbavancin for injection) Side Effects Center for a complete guide to possible side effects
Drug-Laboratory Test Interactions
Drug-laboratory test interactions have not been reported.
No clinical drug-drug interaction studies have been conducted with DALVANCE. There is minimal potential for drug-drug interactions between DALVANCE and cytochrome P450 (CYP450) substrates, inhibitors, or inducers [see CLINICAL PHARMACOLOGY].This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 6/9/2014
Additional Dalvance Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.